TrialWire.AI, the enterprise-grade AI recruitment platform transforming clinical trial enrollment, today announced publication of a landmark industry analysis in Endpoints News, authored by Patricia Stewart, TrialWire’s VP of Growth and Partnerships. The article, “The $50K-a-Day Problem in Clinical Trial Enrollment,” exposes the staggering financial and competitive cost of enrollment delays — and makes the definitive case for AI-driven recruitment as the new standard of clinical development.

With 80% of clinical trials facing enrollment delays and Phase III delays costing sponsors upward of $50,000 per day, the article argues that biotechs still treating recruitment as an afterthought are putting their highest-stakes programs at serious risk.

The $50,000-a-Day Wake-Up Call

The Endpoints News analysis draws on Tufts CSDD data and industry experience to quantify what’s at stake: nearly 90% of trials miss recruitment targets, only 47% complete enrollment on time, and one in six studies takes twice as long as planned. In oncology, CNS, and rare disease — where protocols are complex and eligible patients are narrowly defined — these delays compound daily.

“Biotechs that build AI-enabled recruitment into development now will secure faster, more predictable timelines. Those that don’t will be left scrambling for last-minute ‘rescues’ when milestones slip,” said Susan Fitzpatrick-Napier, CEO & Founder of TrialWire.

From Reactive Campaigns to Always-On Engines

The article contrasts the failing “old playbook” — activate sites, wait, hope, panic, scramble — with the new standard: AI-driven, always-on enrollment engines that continuously find, match, and pre-screen patients from day zero. Key performance metrics from TrialWire’s platform illustrate what this shift delivers in practice:

• 30–45% uplift in eligible referrals versus conventional outreach

• 70% reduction in manual pre-screening time at investigative sites

• 98% site response rates with median response times of 90 seconds

• 24-hour platform activation for trial startup or rescue

“For sponsors, that combination translates into faster, more predictable enrollment curves. For sites, it feels like an extension of their team rather than another system to manage,” Stewart writes in the article.

AI Moves From Buzzword to Business Infrastructure

The article documents a decisive shift in investor expectations. As Stewart notes, sessions at JPM 2026 converged on a single message: investors now reward AI that is embedded in core clinical workflows — not standalone experiments. Anything less reads as execution risk.

TrialWire’s platform is purpose-built to meet this moment. Built on Salesforce Health Cloud, it provides enterprise-grade architecture with role-based access for sites, sponsors, and CROs — designed to satisfy regulatory expectations and enterprise IT requirements. The platform’s risk-share, pay-per-enrollment model aligns incentives around results, not activity.

Answering the Questions Biotech Leaders Are Actually Asking

The Endpoints analysis directly addresses the three questions now dominating conversations in oncology and CNS development:

What will AI actually change for my trials?

AI moves recruitment from reactive bursts to a continuously learning capability that automates eligibility matching at scale — encoding biomarker logic, prior therapy lines, and disease staging directly into matching algorithms. Nearly 30% of trial costs tie to enrollment activities, making any improvement in hit rate disproportionately valuable.

Is AI-driven recruitment acceptable to regulators, sites, and patients?

Global regulators are signaling support for responsible AI with transparency and human oversight. Oncology and neurology centers respond positively when AI removes friction. Automating 70% of pre-screening burden frees sites for patient care and protocol compliance.

Can we trust AI on bias, data quality, and ethics?

TrialWire’s architecture on Salesforce Health Cloud separates identifiable patient information at the site level from sponsor and CRO monitoring dashboards, maintains detailed activity logs, and is designed to meet stringent privacy and security standards.

The Window Is Closing

The article concludes with a direct challenge to sponsors: delay AI adoption and you signal execution risk; embed it from day zero and you own the timelines and predictability that investors reward. As Stewart writes: “By 2027, the question won’t be ‘should we use AI in enrollment?’ It will be: ‘How did we ever run trials without it?’”

About TrialWire.AI

TrialWire is the enterprise-grade AI recruitment platform transforming how biotechs and CROs enroll clinical trials. Built on Salesforce Health Cloud, TrialWire delivers continuously learning, always-on patient identification and matching for complex late-stage studies in oncology, CNS, and rare diseases. With 24-hour activation, risk-share pricing, and proven performance uplifts of 30–45% in eligible referrals, TrialWire is redefining recruitment from tactical necessity to strategic infrastructure. For more information, visit www.trialwire.ai.